Skip to main content
. 2015 Jun 8;10(6):e0123967. doi: 10.1371/journal.pone.0123967

Fig 3. DC-TUSC2 nanovesicles and erlotinib combination treatment inhibits tumor growth and metastases in H322 subcutaneous (A), and A549 metastatic (B) xenograft mouse models.

Fig 3

A) The change of tumor size over time (tumor growth rate or the slope of the linear regression model) differed by treatment (P<0.02 for the interaction between treatment and time). With adjustment for multiple comparisons, the tumor growth rate of the DC-TUSC2 and erlotinib combination group was the only group significantly smaller than the PBS group (P<0.01). The probability of a co-operative effect between DC-TUSC2 and erlotinib was > 0.99; B) Total tumor nodule counts on the lung surface are shown. Wilcoxon rank-sum and Kruskal-Wallis tests were used. The overall difference of the tumor nodule count among the five groups was significant (P<0.0001). The difference between the DC-TUSC2 and erlotinib combination group compared to each of the other groups was significant P<0.01. The probability of a cooperative effect of the DC-TUSC2 and erlotinib combination was >0.99. (C) Resected tumor tissues were assayed by TUNEL. Values represent percentages from at least 1000 counted cells. Fisher's exact test was used. *P< 0.05.